NewsRx

Search our medical news database

Myeloma

Cytokinetics Announces Non-Clinical Trial Data Presented at 2007 AACR Annual Meeting

Published in Cancer Weekly, May 8th, 2007

Cytokinetics, Incorporated (Nasdaq: CYTK) announced the presentation of non-clinical data at the 2007 Annual Meeting of the American Association for Cancer Research (AACR) held in Los Angeles, CA from April 14-18, 2007. The presentations covered data evaluating ispinesib, a novel inhibitor of kinesin spindle protein (KSP), in models of multiple myeloma, data evaluating GSK-923295, a novel inhibitor of centrosome associated protein E (CENP-E) in both biochemical assays and in xenograft models and data from a separate, novel Cytokinetics cell-based drug discovery program.

"These presentations demonstrate the advancement of additional research oncology programs towards...

Want to see the full article?

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Buy Now


Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Weekly


NewsRx is Social

Follow us on your favorite social network by clicking on a button below:

Follow NewsRx on Twitter

NewsRx on Facebook

Awards

eHealthcare Leadership 2011 Winner
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

  • Google 2010 PageRank: #2 Among Top Health News and Media Publications
  • Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
  • Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
  • Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx on Facebook